Articles related to CHEMOTHERAPY

This version of the carboplatin AUC calculator includes a standard multi-clearance output to help you make an informed decision in determining an appropriate final carboplatin dose. Added bonus? Be sure to check the link to the “new version,” which includes the CKD-EPI equation (corrected for BSA) as an additional clearance equation.

Publication: JAMA Oncology Objective: With NSCLC having relatively poor outcomes and the significant data supporting the use of metformin as an antineoplastic agent, the researchers wanted to compare overall or progression-free survival in chemoradiation alone vs. chemoradiation + metformin stage III NSCLC patients. Design: Randomized clinical trial, open-label, phase 2 study; 167 eligible patients

This Original Investigation from JAMA Network Open assesses whether clinically used markers of breast cancer, such as tumor size, tumor grade, progesterone receptor status, and Ki-67 status, are associated with long-term (25-year) survival as they are with short-term survival. The study was a secondary analysis of data from a subset of 565 women who participated in the Stockholm tamoxifen (STO-3) trial from 1976 to 1990.

In this JAMA Original Investigation, the researchers studied 19,529 patients with Medicare coverage who initiated first systemic therapy for advanced non–small cell lung cancer (NSCLC) using 1 of 4 regimens of checkpoint inhibitor immunotherapy, cytotoxic chemotherapy, and combined chemoimmunotherapy. The goal? To gauge the uptake and effectiveness of immunotherapy among older patients outside clinical trials.

As a TROP-2-directed antibody-drug conjugate with an SN-38 payload that has shown preliminary activity in metastatic urothelial carcinoma (mUC), sacituzumab govitecan (SG) – brand name Trodelvy –was evaluated and compared to current treatments to gauge whether SG objective response rates (ORRs) and median overall survival (OS) outperform the average of 10% ORR and 7 to 8 months OS.  

Published recently in Blood, the University of Guelph study highlights a compound only found in avocados – avocatin B – that inhibits the enzyme VLCAD, which is highly prevalent in acute myeloid leukemia (AML). Because the cancer cells rely on this pathway to survive, scientists are hoping to hold human clinical trials to gauge whether avocatin B can be used as a safer, less toxic treatment than traditional chemotherapy.